We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 4

1.
Figure 1.

Figure 1. From: Diabetes Mellitus Is Associated with Increased Mortality in Patients Receiving Curative Therapy for Hepatocellular Carcinoma.

Patient flow diagram.
Abbreviations: DM, diabetes mellitus; HCC, hepatocellular carcinoma; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation.

Wen-Yi Shau, et al. Oncologist. 2012 June;17(6):856-862.
2.
Figure 4.

Figure 4. From: Diabetes Mellitus Is Associated with Increased Mortality in Patients Receiving Curative Therapy for Hepatocellular Carcinoma.

Kaplan-Meier analysis of (A) liver cancer-specific survival, (B) liver disease-related survival, and (C) overall survival of patients with diabetes mellitus, grouped by the usage of insulin or not. Kaplan-Meier analysis of (D) liver cancer-specific survival, (E) liver disease-related survival, and (F) overall survival of patients with diabetes mellitus, grouped by the usage of metformin or not. The p values were conducted by log-rank test.

Wen-Yi Shau, et al. Oncologist. 2012 June;17(6):856-862.
3.
Figure 2.

Figure 2. From: Diabetes Mellitus Is Associated with Increased Mortality in Patients Receiving Curative Therapy for Hepatocellular Carcinoma.

Kaplan-Meier analysis of (A) liver cancer-specific survival, (B) liver disease-related survival, and (C) overall survival of patients with stage I or II hepatocellular carcinoma who received surgery or local therapy. Patients were grouped by diabetes mellitus status. The p values were calculated by log-rank test.

Wen-Yi Shau, et al. Oncologist. 2012 June;17(6):856-862.
4.
Figure 3.

Figure 3. From: Diabetes Mellitus Is Associated with Increased Mortality in Patients Receiving Curative Therapy for Hepatocellular Carcinoma.

Subgroup analysis of adjusted hazard ratios of mortality for patients with and without diabetes mellitus (DM) using the Cox proportional hazard model (the no-DM group is the reference). Every analysis was adjusted for all other factors not involving the subgroup, including sex, age, tumor stage, tumor size, treatment, cirrhosis, and all other comorbidities listed in Table 1. “Favor no-DM” means the hazard ratios favor patients without DM to have better survival outcomes (and vice versa).
Abbreviations: CI, confidence interval; DM, diabetes mellitus; HR, hazard ratio; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation.

Wen-Yi Shau, et al. Oncologist. 2012 June;17(6):856-862.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk